Evidence map›Paper›PMID 35330839›Full record

ArticleFrontiers in pharmacology2022

17α-Hydroxyprogesterone Caproate Inhibits Cytokine Production via Suppression of NF-κB Activation.

Tao Hu, Chengjifu Tang, Sydney Stern, Luan Yang, Tom Du

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tao HuEvergreen Therapeutics, Inc., Bethesda, MD, United States.
Chengjifu TangEvergreen Therapeutics, Inc., Bethesda, MD, United States.
Sydney SternDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States.
Luan YangEvergreen Therapeutics, Inc., Bethesda, MD, United States.
Tom DuEvergreen Therapeutics, Inc., Bethesda, MD, United States.
Evergreen Health Medical Center · USUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine release syndrome (CRS) is one of the leading causes of morbidity and mortality in COVID-19 patients with elevated levels of circulating cytokines contributing to various clinical symptoms. Favorable control of CRS represents a promising and effective strategy to mitigate the clinical outcomes of hospitalized patients with moderate to severe pneumonia. Using

Indexed as

17α-hydroxyprogesterone caproateCOVID-19cytokine release syndromeNF-κBSARS-CoV-2

Identifiers

PMID35330839
PMCPMC8940231
OpenAlexW4221020310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.